CAI - NASDAQ
Caris Life Sciences, Inc.
$15.48
-1.5%Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
At a Glance
Live Snapshotcai
Cash and Short Term Investments
Last Annual Value
800.09M
3-Year CAGR
25%
5-Year CAGR
77%
10-Year CAGR
27%
Caris Life Sciences, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Caris Life Sciences, Inc. NASDAQ:CAI | 800.09M | 87.4% | N/A | 28.3% | |
 Moderna, Inc. NASDAQ:MRNA | 5.80B | -12.3% | -11.6% | 18.5% | |
 Atrium Therapeutics, Inc. NASDAQ:RNA | 270.00M | -23.2% | -7.8% | N/A | |
 Cytokinetics, Incorporated NASDAQ:CYTK | 882.22M | 12.8% | 13.3% | 18.9% | |
 Corcept Therapeutics Incorporated NASDAQ:CORT | 372.15M | 0.4% | 10.7% | 21.9% | |
 Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 983.56M | 15.8% | 29.5% | 37.6% | |
 Jazz Pharmaceuticals plc NASDAQ:JAZZ | 2.44B | 14.5% | 32.8% | 19.1% | |
 Halozyme Therapeutics, Inc. NASDAQ:HALO | 142.82M | -24.8% | -28.1% | -3.5% | |
 Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM | 388.95M | 12.1% | 5.7% | 43.5% |
Caris Life Sciences, Inc. Fair Value Envelope
Related Guides
Continue your CAI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.